Ally Bridge funds lift ProMIS (PMN) stake with 700K-share, warrant deal

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. saw a group of Ally Bridge–affiliated investors report a new insider purchase. On February 3, 2026, they acquired 700,741 Common Shares of ProMIS at $12.13 per share, bringing their indirectly beneficially owned Common Shares to 943,090.

The investors also acquired Warrants to purchase 700,741 Common Shares, with a stated exercise price of $14.40. These Warrants are exercisable immediately and will expire on the earlier of within 60 days after a defined PMN310 topline-data Milestone Event or February 3, 2031.

The Common Shares and Warrants are held across Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with ABG Management Ltd., Ally Bridge Group (NY) LLC, Fan Yu and director Alex Slanix Paul reported as sharing beneficial ownership through various control relationships.

Insider Trade Summary

Net Buyer: 1,401,482 shares ($8,499,988)

Net Buy 2 txns

Insider ABG Management Ltd., Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC, Yu Fan, Alex Slanix Paul

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | Director

Bought 1,401,482 shs ($8.50M)

Type	Security	Shares	Price	Value
Purchase	Warrants	700,741	$0.00	--
Purchase	Common Shares	700,741	$12.13	$8.50M

Holdings After Transaction: Warrants — 700,741 shares (Indirect, See Footnote); Common Shares — 943,090 shares (Indirect, See Footnote)

Footnotes (1)

1. The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited. Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABG Management Ltd.

(Last) (First) (Middle)

#3902, 39/F, E TOWER

10 HARCOURT RD CTR

(Street)

HONG KONG K3

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		P		700,741	A	$12.13(1)	943,090	I	See Footnote(2)(3)(4)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$14.4	02/03/2026		P		700,741		(6)	(6)	Common Shares	700,741	(1)	700,741	I	See Footnote(3)(4)(5)(7)

1. Name and Address of Reporting Person^*

ABG Management Ltd.

(Last) (First) (Middle)

#3902, 39/F, E TOWER

10 HARCOURT RD CTR

(Street)

HONG KONG K3

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Ally Bridge MedAlpha Master Fund L.P.

(Last) (First) (Middle)

C/O MAPLES CORPORATE SERVICES LIMITED,

P.O. BOX 309, UGLAND HOUSE,

(Street)

GRAND CAYMAN, E9

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Ally Bridge Group (NY) LLC

(Last) (First) (Middle)

430 PARK AVENUE, 12TH FLOOR

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Yu Fan

(Last) (First) (Middle)

#3902, 39/F, E TOWER,

10 HARCOURT RD CTR

(Street)

HONG KONG K3

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Alex Slanix Paul

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO, A6 M4S 3E2

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.

2. The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.

3. Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

4. Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

5. Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

6. The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.

7. The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Remarks:

Each of ABG Global Life Science Capital Partners V GP Limited, ABG Global Life Science Capital Partners V GP, L.P., Ally Bridge Group Global Life Science Capital Partners V, L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited will file a Form 3 in connection with the transactions reported herein and thereafter are expected to file Forms 4 jointly with the reporting persons.

	ABG Management Ltd., By: /s/ Fan Yu, Director	02/05/2026
	Ally Bridge MedAlpha Master Fund L.P., By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director	02/05/2026
	Ally Bridge Group (NY) LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director	02/05/2026
	/s/ Fan Yu	02/05/2026
	/s/ Michael Bendetson, Attorney-in-Fact for Slanix Alex	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report on February 3, 2026?

Ally Bridge–affiliated investors bought 700,741 ProMIS Common Shares. They paid $12.13 per share and reported indirect beneficial ownership of 943,090 Common Shares after the trade, reflecting a sizable position managed through several related investment entities.

What Warrants did the Ally Bridge group acquire in ProMIS Neurosciences (PMN)?

The group acquired Warrants for 700,741 ProMIS Common Shares. The Warrants have a stated $14.40 exercise price, are exercisable immediately, and expire on the earlier of within 60 days after a PMN310 topline-data Milestone Event or February 3, 2031.

What was the purchase price for the ProMIS Neurosciences (PMN) shares and Warrants?

The Common Shares and Warrants were purchased at an aggregate $12.13 per Common Share. This price covered both the newly acquired Common Shares and the associated Warrants, as disclosed in the Form 4 explanation of responses footnote.

Which entities now hold the reported ProMIS Neurosciences (PMN) Common Shares?

The 943,090 indirectly owned Common Shares span three Ally Bridge–related entities. These include holdings by Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited, and ABG V-SIV X Limited, with specific share counts detailed for each in the disclosure footnotes.

Who is deemed to share beneficial ownership of the ProMIS Neurosciences (PMN) securities?

Fan Yu and several ABG-related entities may be deemed to share beneficial ownership. Footnotes describe control relationships through ABG Management Ltd., Ally Bridge Group (NY) LLC, and various ABG Global Life Science funds that hold the ProMIS Common Shares and Warrants.

What triggers early expiration of the ProMIS Neurosciences (PMN) Warrants?

The Warrants can expire within 60 days of a specific PMN310 Milestone Event. That Milestone is defined as ProMIS publicly announcing, via press release or Form 8-K, topline data from cohorts treated with single ascending doses of PMN310.